NASDAQ NMS - GLOBAL MARKET · ELDN
-2.13% · -$0.0750 · Vol 743.9K
Market closed · last close 4:00 PM ET · price as of 17:24:43 ET
Eledon Pharmaceuticals Inc

Eledon Pharmaceuticals Inc

Biotechnology
$3.44
Card
Relationship Map

Veridion Score

BETALOW CONF · 4/6 factorsMethodology
Earnings absence reason unknown · Sentiment absence reason unknown
ELDN
Eledon Pharmaceuticals Inc
Fri Aug 21 · last completed session · Markets closed · resumes Mon 9:30 ET
SELL BIAS

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

42/ 100
Veridion Score
SELL BIAS · LOW confidence
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: LOW · 4/6 factors with data · Fri Aug 21 · last completed session · Markets closed · resumes Mon 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is ELDN moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading ELDN catalysts
About Eledon Pharmaceuticals Inc
PHARMACEUTICAL PREPARATIONS
Listed since
2014
Employees
33
Country
US

Eledon Pharmaceuticals Inc is a clinical stage biotechnology company using immunology expertise in targeting the CD40 Ligand pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis. Its compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40L, a well-validated biological target that has broad therapeutic potential. It operates as one reportable segment, focused on the development of tegoprubart, to develop therapies to protect transplanted organs and prevent rejection, and to treat ALS.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$3.54
Day high
$3.58
Day low
$3.41
Previous close
$3.52
52W high
$4.36
-20.99% from high
52W low
$1.39
69% of range
Market cap
$280.4M
EPS
$-0.9400
Beta
0.96
Shares out
81.3M
Volume
743.9K
0.80× rel vol
Avg volume
932.3K
VWAP
$3.47
Price history computed in-house
1W
-3.77%
1M
-3.77%
3M
-11.44%
1Y
+32.50%
YTD
+128.15%
SMA 50 $3.72 · below
SMA 200 $2.90 · above
52W position 69%

ELDN overview

Veridion Score
42
Registered · 2026-08-21
4 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around ELDN.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading ELDN Form 4 filings
Public disclosures

Congress activity in ELDN

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for ELDN in the cached public ledger.

Federal contracts

ELDN contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for ELDN in this window.
Lobbying spend

ELDN lobbying filings, year to date.

Registered lobbying filings matched to Eledon Pharmaceuticals Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for ELDN in this window.
Loading news for ELDN
Analyst ratings
Sovereign unlock shows live analyst consensus for ELDN.
Options
Sovereign unlock shows live options positioning for ELDN.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.